Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Sales | 172,325 | 146,377 | 110,399 | 94,969 | 44,846 |
| Cost of Goods | 20,209 | 19,912 | 22,410 | 8,379 | 7,809 |
| Gross Profit | 152,116 | 126,465 | 87,989 | 86,590 | 37,037 |
| Operating Expenses | 214,415 | 211,894 | 225,479 | 207,410 | 212,929 |
| Operating Income | -62,090 | -84,517 | -137,080 | -120,441 | -175,083 |
| Interest Expense | 6,967 | 7,401 | 7,310 | 7,341 | 7,529 |
| Other Income | 2,804 | 4,765 | 4,386 | 5,939 | 5,116 |
| Pre-tax Income | -66,253 | -87,153 | -140,004 | -121,843 | -177,496 |
| Income Tax | 170 | 1,423 | 233 | 194 | 282 |
| Net Income Continuous | -66,423 | -88,576 | -140,237 | -122,037 | -177,778 |
| Net Income | $-66,423 | $-88,576 | $-140,237 | $-122,037 | $-177,778 |
| EPS Basic Total Ops | -0.54 | -0.70 | -1.17 | -1.02 | -1.56 |
| EPS Basic Continuous Ops | -0.54 | -0.70 | -1.17 | -1.02 | -1.56 |
| EPS Diluted Total Ops | -0.54 | -0.70 | -1.17 | -1.02 | -1.56 |
| EPS Diluted Continuous Ops | -0.54 | -0.70 | -1.17 | -1.02 | -1.56 |
| EPS Diluted Before Non-Recurring Items | N/A | -0.73 | -1.17 | -1.02 | -1.56 |
| EBITDA(a) | $-55,504 | $-57,956 | $-149,678 | $-113,534 | $-167,956 |